IDWeek 2020: Merck will demonstrate its extensive anti-infector drug development pipeline.

Merck today announced that clinical data from its extensive infectious disease and vaccine program will be published in IDWeek 2020 from October 21 to 25, 2020.
this clinical data includes a new subgroup analysis from RESTORE-IMI 2, which assessed the safety of RECARBRIO™ (aamine pernam, sestamine and Rebatan) in adult patients with hospital-acquired or ventilator-related bacterial pneumonia (HABP/VABP) safety and effectiveness, as well as in adult patients 50 years of age and older who have not received anti-HIV-1 treatment, as well as PIFELTRO ™ (doravirine) or DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate).
as part of Merck's commitment to better understanding infectious diseases, Merck researchers will provide epidemiological data.
. Nicholas Kartsonis, Senior Vice President, Merck's Infectious Diseases and Vaccine Research Laboratory, said, "This year, we have all seen the devastating impact that infectious diseases can have on patients and society.
the pandemic urgently requires Merck's continued commitment to addressing the threat of infectious diseases through research."
.